Literature DB >> 31468379

Prognostic usefulness of planar 123I-MIBG scintigraphic images of myocardial sympathetic innervation in congestive heart failure: Follow-Up data from ADMIRE-HF.

Denis Agostini1, Karthikeyan Ananthasubramaniam2, Harish Chandna3, Lars Friberg4, Andrew Hudnut5, Michael Koren6, Michael I Miyamoto7, Roxy Senior8, Mahesh Shah9, Mark I Travin10, Jürgen Vom Dahl11, Kun Chen12, Wayne C Levy13.   

Abstract

BACKGROUND: To evaluate whether planar 123I-MIBG myocardial scintigraphy predicts risk of death in heart failure (HF) patients up to 5 years after imaging. METHODS AND
RESULTS: Subjects from ADMIRE-HF were followed for approximately 5 years after imaging (964 subjects, median follow-up 62.7 months). Subjects were stratified according to the heart/mediastinum (H/M) ratio (< 1.60 vs ≥ 1.60) on planar 123I-MIBG scintigraphic images obtained at baseline in ADMIRE-HF. Cox proportional hazards models and Kaplan-Meier analyses were used to evaluate time to death, cardiac death, or arrhythmic events for subjects stratified by H/M ratio, baseline left ventricular ejection fraction (LVEF: < 25% and 25 to ≤ 35%), and by H/M strata within LVEF strata. All-cause mortality was 38.4% vs 20.9% and cardiac mortality was 16.8% vs 4.5%, in subjects with H/M < 1.60 vs ≥ 1.60, respectively (P < 0.05 for both comparisons). Subjects with preserved sympathetic innervation of the myocardium (H/M ≥ 1.60) were at significantly lower risk of all-cause and cardiac death, arrhythmic events, sudden cardiac death, or potentially life-threatening arrhythmias. Within LVEF strata, a trend toward a higher mortality for subjects with H/M < 1.60 was observed reaching significance for LVEF 25 to ≤ 35% only.
CONCLUSIONS: During a median follow-up of 62.7 months, patients with H/M ≥ 1.60 were at significantly lower risk of death and arrhythmic events independently of LVEF values.
© 2019. American Society of Nuclear Cardiology.

Entities:  

Keywords:  123I-MIBG; cardiac death; congestive heart failure; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31468379     DOI: 10.1007/s12350-019-01859-w

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  11 in total

1.  Do we need further clinical-effectiveness estimates to support the use of primary prevention implantable cardioverter-defibrillators in New York Heart Association class III patients?

Authors:  Sergio Barra; Rui Providencia; Sharad Agarwal
Journal:  Int J Cardiol       Date:  2015-10-22       Impact factor: 4.164

2.  Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death.

Authors:  T Wakabayashi; T Nakata; A Hashimoto; S Yuda; K Tsuchihashi; M I Travin; K Shimamoto
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

3.  Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy.

Authors:  P Merlet; C Benvenuti; D Moyse; F Pouillart; J L Dubois-Randé; A M Duval; D Loisance; A Castaigne; A Syrota
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

4.  Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.

Authors:  Arnold F Jacobson; Roxy Senior; Manuel D Cerqueira; Nathan D Wong; Gregory S Thomas; Victor A Lopez; Denis Agostini; Fred Weiland; Harish Chandna; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2010-02-25       Impact factor: 24.094

5.  ¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study.

Authors:  Jagat Narula; Myron Gerson; Gregory S Thomas; Manuel D Cerqueira; Arnold F Jacobson
Journal:  J Nucl Med       Date:  2015-06-11       Impact factor: 10.057

6.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.

Authors:  Lars Køber; Jens J Thune; Jens C Nielsen; Jens Haarbo; Lars Videbæk; Eva Korup; Gunnar Jensen; Per Hildebrandt; Flemming H Steffensen; Niels E Bruun; Hans Eiskjær; Axel Brandes; Anna M Thøgersen; Finn Gustafsson; Kenneth Egstrup; Regitze Videbæk; Christian Hassager; Jesper H Svendsen; Dan E Høfsten; Christian Torp-Pedersen; Steen Pehrson
Journal:  N Engl J Med       Date:  2016-08-27       Impact factor: 91.245

Review 7.  Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review.

Authors:  Hein J Verberne; Lizzy M Brewster; G Aernout Somsen; Berthe L F van Eck-Smit
Journal:  Eur Heart J       Date:  2008-03-17       Impact factor: 29.983

8.  123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials.

Authors:  Arnold F Jacobson; John Lombard; Gopa Banerjee; Paolo G Camici
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

9.  Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging.

Authors:  Eric S Ketchum; Arnold F Jacobson; James H Caldwell; Roxy Senior; Manuel D Cerqueira; Gregory S Thomas; Denis Agostini; Jagat Narula; Wayne C Levy
Journal:  J Nucl Cardiol       Date:  2012-09-05       Impact factor: 5.952

10.  A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging.

Authors:  Kenichi Nakajima; Tomoaki Nakata; Takahisa Yamada; Shohei Yamashina; Mitsuru Momose; Shu Kasama; Toshiki Matsui; Shinro Matsuo; Mark I Travin; Arnold F Jacobson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-25       Impact factor: 9.236

View more
  3 in total

Review 1.  Cardiac 123I-mIBG Imaging in Heart Failure.

Authors:  Derk O Verschure; Kenichi Nakajima; Hein J Verberne
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

2.  123I-MIBG cardiac sympathetic imaging provides further insight into cardiorenal interactions in systolic heart failure patients.

Authors:  Thomas H Schindler; Sudhir Jain
Journal:  J Nucl Cardiol       Date:  2019-12-24       Impact factor: 5.952

3.  Machine learning-based risk model using 123I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure.

Authors:  Kenichi Nakajima; Tomoaki Nakata; Takahiro Doi; Hayato Tada; Koji Maruyama
Journal:  J Nucl Cardiol       Date:  2020-05-14       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.